On February 1, 2023 Immunocore Holdings Plc (Nasdaq: IMCR), a commercial-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, autoimmune, and infectious diseases, reported that management will present at the following investor conferences in February (Press release, Immunocore, FEB 1, 2023, View Source [SID1234626709]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Guggenheim Oncology Conference
Fireside Chat: Wednesday, February 8, 2023, at 11:20 a.m. ET
SVB Securities Global Biopharma Conference
Fireside Chat: Thursday, February 16, 2023, at 2:20 p.m. ET
Citi’s 2023 Virtual Oncology Leadership Summit
Fireside Chat: Wednesday, February 22, 2023, at 12:00 p.m. ET
The presentations will be webcast live and will be available in the ‘Investors’ section of Immunocore’s website at www.immunocore.com. A replay of the presentations will be made available for a limited time.